Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000173266 | SCV000224362 | pathogenic | not provided | 2015-06-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001377582 | SCV001574952 | likely pathogenic | Maple syrup urine disease | 2023-07-25 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 1 of the DBT gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in DBT are known to be pathogenic (PMID: 16579849, 16786533). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 94003). This variant has not been reported in the literature in individuals affected with DBT-related conditions. This variant is present in population databases (rs398123669, gnomAD no frequency). |
Genome- |
RCV001377582 | SCV002033197 | pathogenic | Maple syrup urine disease | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005016361 | SCV005650991 | likely pathogenic | Maple syrup urine disease type 2 | 2024-05-20 | criteria provided, single submitter | clinical testing |